Cart
sales@molnova.com
Valiglurax
CAS No. 1976050-09-5
Valiglurax( —— )
Catalog No. M34729 CAS No. 1976050-09-5
Valiglurax (VU2957), also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 10MG | 29 | In Stock |
|
| 25MG | 63 | In Stock |
|
| 50MG | 105 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameValiglurax
-
NoteResearch use only, not for human use.
-
Brief DescriptionValiglurax (VU2957), also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species.
-
DescriptionValiglurax (VU0652957) is a potent, orally active and selective mGlu4 positive allosteric modulator with EC50 values of 64.6 nM and 197 nM for hmGlu4/Gqi5 and rmGlu4 GIRK, respectively. Valiglurax is a central nervous system (CNS) penetrant. Valiglurax can be used in research of Parkinson's disease.
-
In Vitro——
-
In VivoAnimal Model:haloperidol-induced catalepsy (HIC) in rats Dosage:0.3-30 mg/kg Administration:Oral administration Result:Reversed haloperidol (HY-14538)-induced catalepsy (HIC) in rats in a dose-dependent manner.
-
Synonyms——
-
PathwayNeuroscience
-
TargetGluR
-
RecptorGluR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1976050-09-5
-
Formula Weight329.28
-
Molecular FormulaC16H10F3N5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 83.33 mg/mL (253.07 mM; Ultrasonic (<60°C)
-
SMILESC(F)(F)(F)C=1C2=C(C=C(NC=3C=4C(NN3)=NC=CC4)C=C2)C=CN1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Panarese JD, et, al. Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease. ACS Med Chem Lett. 2018 Oct 16;10(3):255-260.?
molnova catalog
related products
-
ABP688
ABP688 is a non-competitive and selective mGluR5 antagonist(Ki = 1.7 nM). ABP688 can be used as a PET tracer for clinical imaging.
-
Pyridostatin TFA
Pyridostatin Trifluoroacetate Salt is a G-quadruplexe stabilizer with Kd of 490 nM in a cell-free assay, which targets a series of proto-oncogenes including c-kit, K-ras and Bcl-2.
-
DNQX
DNQX is a competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5 and 0.1 μM for AMPA and kainate receptors respectively).
